SG is an antibody–drug conjugate (ADC) that combines an antibody targeting Trop-2, highly expressed in both aforementioned tumour subtypes, with the active metabolite of irinotecan (SN-38), linked via a hydrolysable linker [8,9]. The gene discussed is TACSTD2; the disease is neoplasm.